Parviz Salehi, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 6670 Reseda Blvd, Suite # 100, Reseda, CA 91335 Phone: 818-343-5109 Fax: 818-343-8770 |
News Archive
Bionumbers, LLC announced top-line figures from the second report in its Parameters of Performance series: "DD09 - Drug Delivery Product Success Rates, Development Times, Costs and Marketing Exclusivity."
Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.
Scientists in Switzerland are uncovering new clues about how cancer cells grow - and how they can be killed - by studying stem cells, 'blank' cells that have the potential to develop into fully mature or 'differentiated' cells and other scientists in UK have made a breakthrough in understanding the cause of the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL).
Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
"With just over one year left to achieve its target of having some 1.1 million men circumcised as part of HIV prevention efforts, Kenya's government is ramping up efforts to bring more men into clinics, compensating them for their time and encouraging them to bring friends in for the procedure," IRIN reports.
› Verified 9 days ago